echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Hengrui Medicine: Docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs

    Hengrui Medicine: Docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 25, Hengrui Pharmaceutical announced that the company's docetaxel injection passed the quality and efficacy consistency evaluation of generic drugs.

    Docetaxel is a paclitaxel anti-tumor drug, which plays an anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function .
    Docetaxel injection was first developed and produced by the French
    company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis).
    It
    applied for a patent in 1986 and was first approved by the European Union for marketing in 1995.
    Up to now it has won in more than 80 countries around the world
    approved to market under the trade name Taxotere®; this product in 2014 approved the listing in China.
    Up to now, in addition to the public
    outside the Division, the country has the Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Aosai Kang and other enterprises approved production, where the Yangtze River Pharmaceutical, CTTQ medicine, Qilu Pharmaceutical, a total of Sichuan Huiyu by 4 (Or deemed to pass) consistency evaluation of generic drugs.
    The company's docetaxel injection has been approved by the US FDA in 2017, and the
    ANDA numbers are 203170 and 207252 respectively.
    After querying the EvaluatePharma database, the global sales of docetaxel injection in 2020 will be approximately US$483 million.

    The necessary microtubule network plays an anti-tumor effect.
    Docetaxel injection was first developed and produced by the French
    company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis).
    It
    applied for a patent in 1986 and was first approved by the European Union for marketing in 1995.
    Up to now it has won in more than 80 countries around the world
    approved to market under the trade name Taxotere®; this product in 2014 approved the listing in China.
    Up to now, in addition to the public
    outside the Division, the country has the Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Aosai Kang and other enterprises approved production, where the Yangtze River Pharmaceutical, CTTQ medicine, Qilu Pharmaceutical, a total of Sichuan Huiyu by 4 (Or deemed to pass) consistency evaluation of generic drugs.
    The company's docetaxel injection has been approved by the US FDA in 2017, and the
    ANDA numbers are 203170 and 207252 respectively.
    After querying the EvaluatePharma database, the global sales of docetaxel injection in 2020 will be approximately US$483 million.

    Up to now, the total R&D expenditure of docetaxel injection (specification: 1ml: 20mg) has been invested in the R&D cost of approximately 4.
    19 million yuan.

    Up to now, the total R&D expenditure of docetaxel injection (specification: 1ml: 20mg) has been invested in the R&D cost of approximately 4.
    19 million yuan.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.